MYMu Yang

Mu Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mu Yang has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Potent and Selective Caspase-2 Inhibitors: Biological Profiling, Structural Characterization, and Challenges of Molecular Instability

    by Lisa Forster, Bernadette Vallaster, Alexander Hubmann, Merlin Bresinsky, Jessica L. Fuller, Ke Shi, Ian P. Lapcinski, Peng Liu, Mu Yang, Jessica M. Strasser, et al.

    Caspase-2 (Casp2) has emerged as a promising therapeutic target for neurodegenerative diseases due to its role in pathological tau processing. Here, we designed and synthesized a series of 48 novel peptidomimetic Casp2 inhibitors organized into distinct structural classes. Compounds were evaluated for Casp2 inhibition and selectivity against Casp1, 3, 4, 5, 6, 7, 8, 9, and 10. Inhibitors Idc(hE)G(Dab)D-CHO (32) and Idc(hE)G((S)-Me-THIQ)D-CHO (33) exhibited low nanomolar potency and ≥537-fold selectivity over Casp3. These unprecedented scaffold modifications are consistent with preferred steric arrangements between the P2 and P3 positions. Biochemical assays demonstrated the blockade of tau truncation and impaired the formation of toxic Δtau314. High-resolution crystal structures of compounds 2 and 33 bound to Casp2 revealed binding interactions consistent with the observed SAR. Although Idc(hE)V((S)-Me-THIQ)D-CHO (3, MUR-65) showed favorable ADME and pharmacokinetic properties, limited membrane permeability, insufficient blood−brain barrier penetration, and P5 indoline instability remain key challenges for further development.

  • Open Access

    Refinement of Peptidomimetics toward MUR-2425: A Brain-Penetrant and Selective Caspase-2 Inhibitor with Enhanced Pharmacokinetics

    by Bernadette Vallaster, Lisa Forster, Merlin Bresinsky, Lukas Wirth, Jessica L. Fuller, Ke Shi, Ian P. Lapcinski, Peng Liu, Deepti Mudaliar, Alexander Hubmann, et al.

    Caspase-2 (Casp2) has emerged as a promising target for tau-associated neurodegenerative diseases, yet the development of potent, selective, and drug-like inhibitors remains challenging. Here, we report a systematic structure–activity relationship study of 80 novel covalent-reversible peptidomimetic Casp2 inhibitors, revealing key structural features of the Casp2 S2–S3 binding site and discovering (S)-2-methylindoline-2-carboxylic acid (2-Me-Idc) and quinaldic acid (Quin) as versatile and stable P5 scaffolds. One-step conversion of the aldehyde warhead into a nitrile remarkably enhanced selectivity while maintaning potency. The results culminate in MUR-2425 (87, (2-Me-Idc)(hE)VP*D-CN), a nanomolar Casp2 inhibitor (pKi (cpCasp2) = 7.75) with ≥525-fold selectivity over Casp1/3/4/5/6/7/9/10 and 24-fold over Casp8. MUR-2425 prevents the formation of neurotoxic Δtau314 in vitro, exhibits stable ADMET properties across human, rat, and mouse species and proves brain penetrance after subcutaneous injection in CD-1 mice. MUR-2425 is confirmed to engage Casp2 covalently by cocrystallization, supporting its further development for Alzheimer’s disease and related dementias.


  • Open Access

    Discovery of Highly Potent C7 Methyl Acetate Substituted Imidazoquinoline-Based TLR7 and TLR8 Agonists

    by John Schultz, Peter Larson, Cara Skon-Hegg, Shubhmita Bhatnagar, Tamara Kucaba, Mu Yang, Jayanth Panyam, Thomas Griffith, David Ferguson

    A series of highly substituted imidazoquinolines were synthesized and evaluated for Toll-like receptor (TLR) 7 and 8 activity and potency in stimulating pro-inflammatory cytokine production. The approach applies structure activity relationship data to evaluate the potentiating effects of ring substitutions to the C7-position. Our results show a clear correlation between the inclusion of a C7 methyl acetate group and TLR7 and 8 activity of substituted imidazoquinoline analogs. The most active compounds identified also contain C2 butyl and N1 aminobenzyl substitutions with several analogs displaying single digit nanomolar TLR7 agonist activity. The immunostimulatory effects of the compounds were further evaluated in vitro using human peripheral blood mononuclear cells (PBMCs) and mouse bone marrow-derived dendritic cells (BMDCs). The most potent compounds induce significant production of TNF-α, IL-1β, and IFN-γ by PBMC and expression of MHC II, CD40, and CD80 on BMDCs. A structural model of the TLR7-agonist complex is presented that shows the C7 acetate forms stabilizing H-bonding contacts with several charged amino acid sidechains near the surface of the receptor. The collective results provide strong evidence that correlates the enhanced potency of the C7 acetate analogs to recognition elements at this new site, providing insight to the design of TLR7 and TLR8 ligands.

  • Proteasomal Stimulation by MK886 and Its Derivatives Can Rescue Tau-Induced Neurite Pathology

    by Elly E. Liao, Mu Yang, Noah Nathan Kochen, Nagamani Vunnam, Anthony R. Braun, David M. Ferguson, Jonathan N. Sachs

    Proteasomal degradation of intrinsically disordered proteins, such as tau, is a critical component of proteostasis in both aging and neurodegenerative diseases. In this study, we investigated proteasomal activation by MK886 (MK). We previously identified MK as a lead compound capable of modulating tau oligomerization in a cellular FRET assay and rescuing P301L tau-induced cytotoxicity. We first confirmed robust proteasomal activation by MK using 20S proteasomal assays and a cellular proteasomal tau-GFP cleavage assay. We then show that MK treatment can significantly rescue tau-induced neurite pathology in differentiated SHSY5Y neurospheres. Due to this compelling result, we designed a series of seven MK analogs to determine if proteasomal activity is sensitive to structural permutations. Using the proteasome as the primary MOA, we examined tau aggregation, neurite outgrowth, inflammation, and autophagy assays to identify two essential substituents of MK that are required for compound activity: (1) removal of the N-chlorobenzyl group from MK negated both proteasomal and autophagic activity and reduced neurite outgrowth; and (2) removal of the indole-5-isopropyl group significantly improved neurite outgrowth and autophagy activity but reduced its anti-inflammatory capacity. Overall, our results suggest that the combination of proteasomal/autophagic stimulation and anti-inflammatory properties of MK and its derivatives can decrease tau-tau interactions and help rebalance dysfunctional proteostasis. Further development of MK to optimize its proteasomal, autophagic, and anti-inflammatory targets may lead to a novel therapeutic that would be beneficial in aging and neurodegenerative diseases.


  • Faculty Opinions recommendation of In Silico Exploration and Biological Evaluation of Bispecific Peptides Derived from Anti-HER2 Antibodies and Peptide-Camptothecin Conjugates for HER2-Positive Breast Cancer.

    by Michael A Walters, Mu Yang

    PDCs (Peptide-drug conjugates) are a class of therapeutic agents that connect a cytotoxic payload to a carrier peptide that either facilitates its tissue and membrane permeation or directs it to the desired target. In this work, the authors designed HER2 (human epidermal growth factor receptor 2) targeting peptides and PDCs by harnessing short sequences of HER2 monoclonal antibodies pertuzumab and trastuzumab from the HER2/antibody interface. Peptides with or without the camptothecin payload consistently showed optimal co-localization with HER2 in cell imaging. PDCs with camptothecin showed levels of topoisomerase inhibition comparable to the payload alone. Discrepancies in cytotoxicity were also observed in HER2 positive cells and HER2 negative cells. Moreover, in vivo treatment of PDCs vs. payload alone showed comparable tumor reduction but improved safety profiles, as demonstrated by reduced weight loss and lessened increase of liver enzymes. Overall, conjugating camptothecin and a HER2-directing peptide originated from monoclonal antibodies proved to be a viable approach to improve target engagement without compromising drug potency. PDCs are highly pursued in drug discovery. Many of the peptides used in these complexes are cell-permeating, including poly-arginine/lysine and translocating toxin moieties like TAT (Trans-Activator of Transcription) of HIV, anthrax toxin and transportan. These peptides facilitate cellular internalization of payloads that were otherwise impermeable. But cell-permeable peptides do not provide enough selectivity or tissue specificity. In comparison, PDCs with cell-targeting peptides as carriers most resemble the concept of antibody-drug conjugates (ADCs). Although peptides rarely deliver premium target specificity like full antibodies, they are superior in other aspects including enhanced tissue penetration, reduced immunogenicity side effects, and more importantly, the lowered difficulty in preparation and purification. While the scope of this approach is currently limited to a handful of targets including integin (targeted by the well-known RGD), EGFR (epidermal growth factor receptor), SSTR2 (somatostatin receptor 2), GRPR-2 (gastrin-releasing peptide receptor 2), this study is first to add HER2 to the growing list. This approach can serve as a powerful alternative to ADCs in targeted therapies.

  • Faculty Opinions recommendation of A Toolkit for Engineering Proteins in Living Cells: Peptide with a Tryptophan-Selective Ru-TAP Complex to Regioselectively Photolabel Specific Proteins.

    by Michael A Walters, Mu Yang

    This article is recommended because it presents a novel approach in target-selective and site-selective protein labelling/modification. From a bioinorganic chemistry point of view, it also provides an example of target-directed functionalization by a reactive Ru(II) moiety. The paper introduces the strategy by which a Ru(II)-TAP(1,4,5,8-tetraazaphenanthrene) warhead can be conjugated to a protein kinase A (PKA)-targeting peptide. This Ru(II) probe selectively labels PKA amongst a variety of proteins in cell lysates and W196 amongst four total tryptophan residues in PKA. Additionally, the probe features both photoinduced caging and uncaging properties via blue light and UV radiation, respectively. The authors demonstrated the process of peptide-directed lodging of the probe to the protein of interest, followed by blue light induced Ru-TAP tryptophan crosslinking, along with the subsequent liberation of the peptide payload from Ru via UV radiation. Overall, a Ru(II)-TAP moiety alone was installed onto the W196 of PKA. The process was verified on protein and cellular levels. Ruthenium complexes bear unique reactivity that organic scaffolds do not possess. Photoreactive ruthenium complexes such as Ru-TAP and Ru(bipy) have been used in a variety of cases as inducers of cytotoxic singlet oxygen and ROS for the catalysis of protein crosslinking (e.g., the PICUP [photo-induced cross-linking of unmodified proteins] method and this case) and as a site for light-promoted ligand exchange. Ruthenium compound NAMI-A is a DNA intercalator/covalent binder that has advanced into clinical trials as an anti-cancer agent. Ruthenium arene complexes have also been used as cysteine-promoted allyl and propargyl-uncaging catalysts. While these examples of Ru chemistry are fascinating, few studies focus on target-selective delivery of the transition-metal warhead. The use of these Ru reagents is often limited by the off-target reactions. Therefore, the highlight of this study is that the reactivity of Ru(II) is cleverly directed to the protein of interest and in a light-controlled fashion, sparing other proteins from being affected. Moreover, the light-induced uncaging of the protein-binding peptide could also be applied as a photo-switch monitoring enzyme activity or protein-protein interactions.

  • Toll-like receptor 7 and 8 imidazoquinoline-based agonist/antagonist pairs

    by Mu Yang, Peter G. Larson, Lincoln Brown, John R. Schultz, Tamara A. Kucaba, Thomas S. Griffith, David M. Ferguson